Related Experiment Video
Updated: Aug 24, 2025
12:40
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
15.0K
New Indication for Topical Ruxolitnib.
1Diane S. Aschenbrenner is a former member of the faculty at Notre Dame of Maryland University and the Johns Hopkins University School of Nursing. She coordinates Drug Watch : diane.aschenbrenner@gmail.com .
The American Journal of Nursing
|October 20, 2022
Summary
The U.S. Food and Drug Administration (FDA) approved ruxolitinib (Opzelura) cream for nonsegmental vitiligo in individuals 12 and older. This topical Janus kinase inhibitor offers a new treatment option for this autoimmune skin condition.
Area of Science:
- Dermatology
- Immunology
- Pharmacology
Background:
- Vitiligo is a chronic autoimmune condition characterized by depigmentation of the skin.
- Current treatment options for vitiligo have limitations in efficacy and safety.
- Janus kinase (JAK) inhibitors have emerged as a potential therapeutic class for immune-mediated diseases.
Purpose of the Study:
- To report the U.S. Food and Drug Administration (FDA) approval of topical ruxolitinib (Opzelura) for nonsegmental vitiligo.
- To highlight the target patient population and the drug's mechanism of action.
Main Methods:
- The U.S. Food and Drug Administration (FDA) reviewed clinical trial data for topical ruxolitinib.
- The review focused on safety and efficacy in treating nonsegmental vitiligo.
Main Results:
- Topical ruxolitinib (Opzelura) is approved for treating nonsegmental vitiligo in patients aged 12 years and older.
- Common adverse effects include application site acne, itching, redness, and systemic effects like headache and fever.
Conclusions:
- Ruxolitinib (Opzelura) represents a significant advancement in the topical treatment of nonsegmental vitiligo.
- The approval provides a new therapeutic option for a patient population with limited effective treatments.
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
250
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
250
01:29Drugs for Treatment of Ulcerative Colitis in IBD
223
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
223
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
188
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
188
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
219
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
219
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
01:22PI3K/mTOR/AKT Signaling Pathway
3.8K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.8K